Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment landscape for head and neck and lung cancer, and implications for specific drug ...

In the rapidly evolving landscape of oncology, precision is the cornerstone of progress. A leading biopharmaceutical company ...

Summit Therapeutics (NASDAQ:SMMT) stock extends gains as lead cancer drug ivonescimab developed with Akeso (AKESF) ...

BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.

Analysts at BMO Capital Markets expect Summit and Akeso's HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

Summit Therapeutics and Akeso said their PD-1xVEGF bispecific antibody ivonescimab beat BeiGene’s PD-1 blocker Tevimbra in a ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of lung cancer.

Shares Genomics Immunology and Healthcare ETF offers biotech exposure but lacks performance and stability versus PBE. Find ...

The firms will use nFerence's Agentic AI platform to analyze real-world treatment patterns in 700 patients' charts and inform personalized care.